Comparisons of the therapeutic safety of seven oral antimuscarinic drugs in patients with overactive bladder: a network meta-analysis

Comparisons of the therapeutic safety of seven oral antimuscarinic drugs in patients with overactive bladder: a network meta-analysis

Objectives This network meta-analysis aimed to assess the safety profiles of seven commonly used oral antimuscarinic drugs (darifenacin, fesoterodine, imidafenacin, oxybutynin, propiverine, solifenacin, and tolterodine) in patients with overactive bladder (OAB). Methods PubMed, Cochrane Library, EMB...

Full description

Bibliographic Details
Main Authors:	Nannan Yang, Qiaoyan Wu, Faren Xu, Xiaopeng Zhang
Format:	Article
Language:	English
Published:	SAGE Publishing 2021-09-01
Series:	Journal of International Medical Research
Online Access:	https://doi.org/10.1177/03000605211042994

Similar Items

A meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladder
by: Creanga Dana, et al.
Published: (2009-07-01)

Effect of Antimuscarinic Drugs on Cognitive Functions in the Management of Overactive Bladder in Elderly
by: Ervandy Rangganata, et al.
Published: (2020-10-01)

An Overview of the Clinical Use of Antimuscarinics in the Treatment of Overactive Bladder
by: Anastasios Athanasopoulos, et al.
Published: (2011-01-01)

The challenge of overactive bladder therapy: alternative to antimuscarinic agents
by: Massimo Lazzeri, et al.
Published: (2006-12-01)

Patterns of use of antimuscarinic drugs to treat overactive bladder in Denmark, Sweden, and the United Kingdom.
by: Andrea V Margulis, et al.
Published: (2018-01-01)

Maintenance of the Therapeutic Effect of Two High-Dosage Antimuscarinics in the Management of Overactive Bladder in Elderly Women
by: Kirill Kosilov, et al.
Published: (2013-12-01)

Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach.
by: Thomas M Kessler, et al.
Published: (2011-01-01)

Cost-effectiveness of solifenacin compared with oral antimuscarinic agents for the treatment of patients with overactive bladder in the UK
by: Zalmai Hakimi, et al.
Published: (2018-01-01)

Choice of antimuscarinic agents for overactive bladder in the older patient: focus on darifenacin
by: Bilal Chughtai, et al.
Published: (2008-09-01)

Urodynamic evaluation of antimuscarinic drug effect on lower urinary tract function in women with overactive bladder
by: Wen-Yih Wu, et al.
Published: (2006)

Comparison of objective and subjective factors in the adherence to antimuscarinics when treating overactive bladder in employed persons
by: Kirill Vladimirovich Kosilov, et al.
Published: (2017-12-01)

Factors associated with antimuscarinic drug persistence and increasing drug persistence after switching to mirabegron for overactive bladder patients
by: Chung-Cheng Wang, et al.
Published: (2019-01-01)

Compared Cost-Effectiveness of Solifenacin with Other Antimuscarinics in Patients with Overactive Bladder Symptoms: Systematic Reviews and Meta-Analysis
by: Yu-Cheng Chang, et al.
Published: (2017)

Treatment success for overactive bladder with urinary urge incontinence refractory to oral antimuscarinics: a review of published evidence
by: Ravelo Arliene, et al.
Published: (2009-11-01)

Exposure to antimuscarinic medications for treatment of overactive bladder and risk of lung cancer and colon cancer
by: Löfling L, et al.
Published: (2019-01-01)

Long-term adherence to antimuscarinic drugs when treating overactive bladder in the older: Subjective reason and objective factors
by: Kirill Vladimirovich Kosilov, et al.
Published: (2017-03-01)

Antimuscarinic Agent Treatment Affecting Patient-Reported Outcomes in Overactive Bladder Syndrome With Depressive Symptoms
by: Kyu Shik Kim, et al.
Published: (2016-12-01)

Increased serum adipokines implicate chronic inflammation in the pathogenesis of overactive bladder syndrome refractory to antimuscarinic therapy.
by: Hsin-Tzu Liu, et al.
Published: (2013-01-01)

A retrospective study of treatment persistence and adherence to mirabegron versus antimuscarinics, for the treatment of overactive bladder in Spain
by: Jameel Nazir, et al.
Published: (2018-09-01)

Cost-effectiveness analysis of antimuscarinics in the treatment of patients with overactive bladder in Spain: A decision-tree model
by: Trocio Jeffrey, et al.
Published: (2011-05-01)

The Forefront for Novel Therapeutic Agents Based on the Pathophysiology of Lower Urinary Tract Dysfunction: Bladder Selectivity Based on In Vivo Drug–Receptor Binding Characteristics of Antimuscarinic Agents for Treatment of Overactive Bladder
by: Akira Yoshida, et al.
Published: (2010-01-01)

Duration of Antimuscarinic Administration for Treatment of Overactive Bladder Before Which One Can Assess Efficacy: An Analysis of Predictive Factors
by: Sheng-Mou Hsiao, et al.
Published: (2015-09-01)

Characterization of Bladder Selectivity of Antimuscarinic Agents on the Basis of Drug-Receptor Binding
by: Shizuo Yamada, et al.
Published: (2012-09-01)

Additional low-dose antimuscarinics can improve overactive bladder symptoms in patients with suboptimal response to beta 3 agonist monotherapy
by: Jung Hyun Shin, et al.
Published: (2017-07-01)

Real life persistence rate with antimuscarinic treatment in patients with idiopathic or neurogenic overactive bladder: a prospective cohort study with solifenacin
by: Marloes J. Tijnagel, et al.
Published: (2017-04-01)

Efficacy and safety of dose escalation in male patients with overactive bladder showing poor efficacy after low-dose antimuscarinic treatment: A retrospective multicenter study
by: Myungsun Shim, et al.
Published: (2020-11-01)

Comparative persistence, switch rates, and predictors for discontinuation of antimuscarinics for overactive bladder: A 10-year nationwide population-based study in Taiwan
by: Hao-Wei Chen, et al.
Published: (2018-01-01)

The efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy: results of a noninferiority, randomized, phase IIIb trial
by: Jose E. Batista, et al.
Published: (2015-08-01)

Protective Effects of Antimuscarinics on the Bladder Remodeling After Bladder Outlet Obstruction
by: Qiang Liu, et al.
Published: (2017-11-01)

The Forefront for Novel Therapeutic Agents Based on the Pathophysiology of Lower Urinary Tract Dysfunction: Ameliorative Effect of Solifenacin Succinate (Vesicare ®), a Bladder-Selective Antimuscarinic Agent, on Overactive Bladder Symptoms, Especially Urgency Episodes
by: Akiyoshi Ohtake, et al.
Published: (2010-01-01)

Editorial Comment: Comparative Persistence, Switch Rates, and Predictors for Discontinuation of Antimuscarinics for Overactive Bladder: A 10-year Nationwide Population-based Study in Taiwan
by: En Meng
Published: (2018-01-01)

Meta-Analysis of the Efficacy and Safety of Mirabegron Add-On Therapy to Solifenacin for Overactive Bladder
by: Yankai Xu, et al.
Published: (2017-09-01)

Urodynamic and Bladder Diary Factors Predict Overactive Bladder-wet in Women: A Comparison With Overactive Bladder-dry
by: Sheng-Mou Hsiao, et al.
Published: (2019-03-01)

The overactive bladder
by: Richard Foon, et al.
Published: (2010-08-01)

Overactive bladder
by: Anna Zwierzyńska
Published: (2021-07-01)

Transdermal drug delivery treatment for overactive bladder
by: Roger R. Dmochowski, et al.
Published: (2006-10-01)

The Prevalence and Therapeutic Effect of Constipation in Pediatric Overactive Bladder
by: Ji Hyun Kim, et al.
Published: (2011-12-01)

Associations of bladder antimuscarinics with delirium and antipsychotics utilization in nursing homes in Iowa
by: Zhang, Yan
Published: (2018)

Refractory overactive bladder: Beyond oral anticholinergic therapy
by: Ronald W Glinski, et al.
Published: (2007-01-01)

The Antimuscarinic Agent Tolterodine Regulates Bladder Extracellular Matrix in Partial Bladder Outlet Obstruction in Rats
by: Tong-Xin Yang, et al.
Published: (2018-03-01)